Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 11—November 2003
Research

Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients1

Stephen G. Weber*Comments to Author , Howard S. Gold*, David C. Hooper†, A.W. Karchmer*, and Yehuda Carmeli*
Author affiliations: *Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; †Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Main Article

Table 3

Results of univariate analysis for MSSA casesa

Risk factor MSSA cases (n = 163)
Demographic
No.
%
OR (95% CI)
p value
Male
91
55.8
1.89 (1.29 to 2.77)
0.001
Age
Mean = 63.3 y.



<50
42
25.8


51–75
68
41.7
1.50 (0.95 to 2.37)
0.08
>75
53
32.5
2.10 (1.27 to 3.45)
0.004
Coexisting condition




Cardiovascular disease
117
71.8
2.08 (1.39 to 3.13)
<0.001
Lung disease
61
37.4
2.95 (1.92 to 4.54)
<0.001
Renal disease
28
17.2
2.06 (1.17 to 3.62)
0.01
Hepatic disease
24
14.7
3.16 (1.64 to 6.10)
<0.001
Organ transplant
2
1.2
1.00 (0.18 to 5.60)
0.99
AIDS
1
0.6
0.39 (0.00 to 3.42)
0.40
Malignancy
30
18.4
1.21 (0.74 to 1.98)
0.46
Diabetes mellitus
38
23.3
1.25 (0.80 to 1.98)
0.33
Hospital factors




Transfer
29
17.8
2.11 (1.22 to 3.64)
0.01
Surgical procedure
62
38.0
0.78 (0.52 to 1.15)
0.20
ICU stay
89
54.6
6.38 (4.14 to 9.83)
<0.001
Intravenous line
50
30.7
1.99 (1.28 to 3.09)
0.002
Emergent admission
97
59.5
1.90 (1.30 to 2.79)
<0.001
Admission service




Medical
85
52.1


Obstetrical
3
1.8
0.10 (0.03 to 0.34)
<0.001
Surgical
75
46.0
1.49 (1.00 to 2.21)
0.05
Antimicrobial drugs




Any fluoroquinolone
37
22.7
0.96 (0.60 to 1.53)
0.86
Levofloxacin
24
14.7
1.09 (0.62 to 1.90)
0.77
Ciprofloxacin
14
8.6
0.74 (0.38 to 1.44)
0.37
Vancomycin
31
19.0
1.78 (1.04 to 3.05)
0.36
Penicillin
33
20.2
2.17 (1.28 to 3.66)
0.004
β-lactam and inhibitor
6
3.7
2.37 (0.70 to 8.06)
0.17
First-generation cephalosporin
27
16.6
0.65 (0.40 to 1.07)
0.09
Third-generation cephalosporin
18
11.0
1.21 (0.64 to 2.30)
0.56
Carbapenem
2
1.2
1.05 (0.17 to 6.48)
0.96
Clindamycin
6
3.7
1.35 (0.47 to 3.91)
0.58
Metronidazole 34 20.9 1.70 (1.02 to 2.83) 0.04

a MsSA, methicillin-susceptible Staphylococcus aureus; OR, odds ration; CI, confidence interval.

Main Article

1This study was presented in part at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Sand Diego, California, September 2002.

Page created: January 21, 2011
Page updated: January 21, 2011
Page reviewed: January 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external